Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap

• U.S. Patent No. 12,042,482 specifically addresses traumatic brain injury (“TBI”) treatment with buntanetap, enhancing Annovis Bio’s portfolio that includes various patents and applications for using buntanetap in treating both acute and chronic neurodegenerative diseases and mental illnesses
• Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43
• TBI is one of the major causes of death and disability in the US with annual death rate exceeding 70,000

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced the issuance of a U.S. patent for treating traumatic brain injury (“TBI”) with its lead drug candidate, buntanetap. Initially filed in 2016, the patent covered treatments for various nerve injuries, including TBI, stroke, and spinal cord injuries, but required division into individual patents by the USPTO. Now, U.S. Patent No. 12,042,482, which specifically addresses the treatment of TBI and nerve injury with buntanetap, is successfully added in Annovis Bio’s diverse portfolio covering treatments for multiple acute and chronic neurodegenerative diseases and mental illnesses (https://ibn.fm/tU6FR).

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution for neurodegenerative diseases.

Maria Maccecchini, Ph.D., the company’s Founder, President, and CEO, highlighted the importance of this milestone, noting the drug’s demonstrated efficacy in preventing nerve cell death in preclinical TBI and stroke models. “We are thrilled to achieve this significant milestone for buntanetap. Nerve cell death is a common underlying factor in many brain conditions, beyond just Alzheimer’s and Parkinson’s,” Maccecchini said. “Our preclinical studies in TBI and stroke animal models have demonstrated buntanetap’s efficacy in preventing cell death and loss of function, and it is our duty to explore its potential benefits for victims of brain trauma, a prevalent issue in the U.S.”

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy, with early Alzheimer’s patients showing substantial improvement in cognitive scores and reduced plasma Tau protein levels. Similarly, findings from the Phase III study in Parkinson’s disease (“PD”) patients indicate promising results in several disease subpopulations, where the drug improved PD-related functions and halted cognitive decline.

Annovis has a unique market position as the only company developing a drug that inhibits multiple neurotoxic proteins for both Alzheimer’s disease and Parkinson’s disease, distinguishing it from other industry players. The company’s commitment is evident in its approach to restoring brain function and improving patient outcomes, highlighting its dedication to pioneering effective therapies in this critical field.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN